Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Hamm – page 8

1 110 clinical trials in Hamm, Germany across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Hamm at a glance
1 110
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

1 110 trials in Hamm

Open in trial search

Phase 3 Study of Enfortumab Vedotin plus Pembrolizumab in Adults with Muscle‑Invasive Bladder Cancer Ineligible for Cystectomy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Enfortumab Vedotin
  • Sponsor:Pfizer Inc.

Study of LY3537982, pembrolizumab, and a drug combination for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Eli Lilly & Co.

Phase 3 Study of Pridopidine Hydrochloride for Safety and Efficacy in Adults with Huntington’s Disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pridopidine hydrochloride
  • Sponsor:Ferrer Internacional S.A.

Phase III trial evaluating ianalumab with background drug combination in patients with Sjögren's disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Emtricitabine
  • Sponsor:Novartis Pharma AG

Influenza+1

Recruiting

Efficacy and safety of the investigational mRNA influenza vaccine gskvx000000077430 (drug combination) in adults ≥ 65 years

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:65+ years · Healthy volunteers
  • Substances:GSKVX000000077430
  • Sponsor:GlaxoSmithKline Biologicals

Adjuvant Datopotamab Deruxtecan with Drug Combination in Patients with High‑Risk Muscle‑Invasive Urothelial Carcinoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Obesity

Recruiting

Long‑term Efficacy, Safety and Tolerability of maridebart cafraglutide in Adults with Obesity and Type 2 Diabetes

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Adults with Moderate to Severe Atopic Dermatitis (Phase 2 Study)

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Soquelitinib
  • Sponsor:Corvus Pharmaceuticals Inc.

A Phase III Randomized Trial of Trilaciclib Dihydrochloride versus Placebo in Adults with Limited‑Stage Small Cell Lung Cancer

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Trilaciclib dihydrochloride
  • Sponsor:Pharmacosmos A/S

Ramantamig (JNJ-79635322) with drug combination versus standard therapy in newly diagnosed multiple myeloma patients not eligible for stem cell transplant

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Study of belumosudil versus drug combination in patients aged 12 years and older with chronic graft‑versus‑host disease refractory after prior therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Belumosudil
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Efficacy, safety and dose‑response of once‑weekly subcutaneous UBT251 compared with semaglutide in adults with type 2 diabetes

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

Other cities in Germany

The busiest research cities in the country

All 503 cities in Germany

Clinical research in Hamm

What the registry says about research in the country

01 Hematologic Oncology

Innovative clinical trials focusing on blood cancers and related disorders, including studies of new treatment approaches for chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia.

  • Novel drug combinations for CLL/SLL treatment
  • Multiple myeloma therapies
  • Advanced leukemia treatments

Research emphasizes personalized medicine approaches and targeted therapies to improve patient outcomes.

02 Solid Tumors

Comprehensive research into various types of solid tumors, with particular focus on breast cancer, lung cancer, and gastrointestinal cancers.

  • Triple-negative breast cancer treatments
  • Non-small cell lung cancer therapies
  • Colon cancer interventions

Studies explore both neoadjuvant and adjuvant treatment approaches.

03 Dermatological Conditions

Clinical investigations of various skin conditions, including actinic keratosis, rosacea, and atopic dermatitis.

  • Novel topical treatments
  • Comparative efficacy studies
  • Inflammatory skin conditions

Research focuses on both innovative and established therapeutic approaches for skin disorders.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.